Sinopharm Group Co (X2S) Stock Statistics & Valuation Metrics
Total Valuation
Sinopharm Group Co has a market cap or net worth of EUR 5.77B. The enterprise value is EUR 183.65B.
- Market Cap
- EUR 5.77B
- Enterprise Value
- EUR 183.65B
Share Statistics
Sinopharm Group Co has 1,341,810,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,341,810,800
- Owned by Insiders
- ―
- Owned by Institutions
- 24.47%
Financial Efficiency
Sinopharm Group Co’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 5.63%.
- Return on Equity (ROE)
- 0.09
- Return on Assets (ROA)
- 0.02
- Return on Invested Capital (ROIC)
- 5.63%
- Return on Capital Employed (ROCE)
- 0.11
- Revenue Per Employee
- 6.06M
- Profits Per Employee
- 75.39K
- Employee Count
- 94,910
- Asset Turnover
- 1.47
- Inventory Turnover
- 8.42
Valuation Ratios
The current PE Ratio of Sinopharm Group Co is 6.09. Sinopharm Group Co’s PEG ratio is 1.90.
- PE Ratio
- 6.09
- PS Ratio
- 0.08
- PB Ratio
- 0.50
- Price to FCF
- 2.29
- Price to Operating Cash Flow
- 2.12
- PEG Ratio
- 1.90
Income Statement
In the last 12 months, Sinopharm Group Co had revenue of 575.17B and earned 7.16B in profits. Earnings per share was 2.29.
- Revenue
- 575.17B
- Gross Profit
- 41.67B
- Operating Income
- 16.04B
- Pretax Income
- 14.80B
- Net Income
- 7.16B
- EBITDA
- 21.52B
- Earnings Per Share (EPS)
- 2.29
Cash Flow
In the last 12 months, operating cash flow was 20.16B and capital expenditures -1.47B, giving a free cash flow of 18.69B billion.
- Operating Cash Flow
- 20.16B
- Free Cash Flow
- 18.69B
- Free Cash Flow per Share
- 5.99
Dividends & Yields
Sinopharm Group Co pays an annual dividend of ―, resulting in a dividend yield of 4.27%
- Dividend Per Share
- ―
- Dividend Yield
- 4.27%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 43.69%
- Earnings Yield
- 16.47%
Stock Price Statistics
- Beta
- 0.28
- 52-Week Price Change
- -14.51%
- 50-Day Moving Average
- 1.71
- 200-Day Moving Average
- 1.91
- Relative Strength Index (RSI)
- 59.56
- Average Volume (3m)
- 5,435
Important Dates
Sinopharm Group Co upcoming earnings date is Mar 19, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 25, 2026
- Next Earnings Date
- Mar 19, 2027
- Ex-Dividend Date
- ―
Financial Position
Sinopharm Group Co as a current ratio of 1.41, with Debt / Equity ratio of 129.33%
- Current Ratio
- 1.41
- Quick Ratio
- 1.15
- Debt to Market Cap
- 1.23
- Net Debt to EBITDA
- 2.19
- Interest Coverage Ratio
- 6.97
Taxes
In the past 12 months, Sinopharm Group Co has paid 3.97B in taxes.
- Income Tax
- 3.97B
- Effective Tax Rate
- 0.27
Enterprise Valuation
Sinopharm Group Co EV to EBITDA ratio is 3.78, with an EV/FCF ratio of 4.40.
- EV to Sales
- 0.14
- EV to EBITDA
- 3.78
- EV to Free Cash Flow
- 4.40
- EV to Operating Cash Flow
- 4.08
Balance Sheet
Sinopharm Group Co has EUR 41.88B in cash and marketable securities with EUR 81.32B in debt, giving a net cash position of -EUR 39.44B billion.
- Cash & Marketable Securities
- EUR 41.88B
- Total Debt
- EUR 81.32B
- Net Cash
- -EUR 39.44B
- Net Cash Per Share
- -EUR 29.39
- Tangible Book Value Per Share
- EUR 41.12
Margins
Gross margin is 7.03%, with operating margin of 2.95%, and net profit margin of 1.24%.
- Gross Margin
- 7.03%
- Operating Margin
- 2.95%
- Pretax Margin
- 2.54%
- Net Profit Margin
- 1.24%
- EBITDA Margin
- 3.83%
- EBIT Margin
- 3.11%
Analyst Forecast
The average price target for Sinopharm Group Co is EUR 2.38, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 2.38
- Price Target Upside
- 30.00% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 3
- Revenue Growth Forecast
- -4.46%
- EPS Growth Forecast
- 0.14%
Scores
- Smart Score
- 7
- AI Score
- ―
